secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001193125-24-038473
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics closes $161.8M public offering of 19.7M shares at $8.74
----------------------------------------------------------------------------

- Offered 17,162,472 shares plus 2,574,370 option shares exercised immediately.
- Net proceeds ~$161.8M after underwriting discounts and estimated expenses.
- Joint bookrunners: Leerink Partners, Citigroup, Guggenheim Securities.
- All shares sold by company; offering closed February 16, 2024.
- Proceeds will support clinical development of nomlabofusp (CTI-1601) and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312524038473/0001193125-24-038473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312524038473/d780024d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-038473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer